|drug593||COVID visitation restrictions Wiki||1.00|
|D013896||Thoracic Diseases NIH||1.00|
|D006331||Heart Diseases NIH||0.38|
There is one clinical trial.
In this study, defined cases of COVID-19 confirmed with PCR, with a mild, moderate or severe pneumonia will be treated with chlorpromazine. The improvement in clinical & laboratory manifestations will be evaluated in treated patient compared to control group.
Description: In the current study, the clinical improvement will be determined by: Temperature Heart rate (pulse) Respiratory rate Oxygen saturation Need for oxygen Hospital stay time. CT lung involvement at day 0 and day 14.Measure: Clinical improvement Time: 2 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports